|
業務類別
|
Biotechnology |
|
業務概覽
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
| 公司地址
| 50 Northern Avenue, Boston, MA, USA, 02210 |
| 電話號碼
| +1 617 341-6100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.vrtx.com |
| 員工數量
| 6400 |
| Mr. Amit K. Sachdev, J.D. |
Executive Vice President and Chief Patient and External Affairs Officer |
-- |
13/02/2026 |
| Mr. Charles F. Wagner, Jr |
Executive Vice President, Chief Operating Officer and Chief Financial Officer |
美元 876.44K |
13/02/2026 |
| Dr. David Altshuler, M.D.,PhD |
Executive Vice President and Chief Scientific Officer |
美元 876.44K |
04/08/2025 |
| Mr. Mark E. Bunnage, D.Phil. |
Executive Vice President and Chief Scientific Officer |
-- |
13/02/2026 |
| Dr. Reshma Kewalramani, M.D. |
Director, President and Chief Executive Officer |
美元 1.54M |
13/02/2026 |
| Mr. Duncan J. McKechnie |
Executive Vice President and Chief Commercial Officer |
-- |
13/02/2026 |
| Dr. Ourania Tatsis, PhD |
Executive Vice President and Chief Regulatory and Quality Officer |
-- |
13/02/2026 |
| Dr. Carmen Bozic |
Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer |
-- |
13/02/2026 |
| Dr. E Morrow Atkinson, III, PhD |
Executive Vice President, Chief Technical Operations Officer and Head, Biopharmaceutical Science and Manufacturing Operations |
-- |
13/02/2026 |
| Ms. Kristen C. Ambrose |
Senior Vice President and Chief Accounting Officer |
-- |
13/02/2026 |
| Mr. Jonathan Biller |
Executive Vice President and Chief Legal Officer |
-- |
13/02/2026 |
|
|
| Mr. Michel Lagarde |
Independent Director |
13/02/2026 |
| Mr. Bruce I. Sachs |
Lead Independent Director |
13/02/2026 |
| Mr. Lloyd A. Carney |
Independent Director |
13/02/2026 |
| Dr. Jeffrey M Leiden, PhD |
Executive Chairman of the Board |
13/02/2026 |
| Dr. Alan M. Garber, M.D.,PhD |
Independent Director |
13/02/2026 |
| Mr. Suketu Upadhyay |
Independent Director |
13/02/2026 |
| Dr. Sangeeta N. Bhatia, PhD |
Independent Director |
13/02/2026 |
| Ms. Diana L. McKenzie |
Independent Director |
13/02/2026 |
| Dr. Reshma Kewalramani, M.D. |
Director, President and Chief Executive Officer |
13/02/2026 |
| Ms. Nancy A. Thornberry |
Independent Director |
13/02/2026 |
| Dr. Jennifer Schneider, M.D. |
Independent Director |
13/02/2026 |
|
|
|
|
